FTSE MIB
33.565,96 -315,54 (-0,93%) Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,70 +0,97 (+1,17%) Bitcoin EUR
60.496,08 +2.898,11 (+5,03%)
CSL Limited (CSL.AX)
| Chiusura precedente | 271,40 |
| Aperto | 270,01 |
| Denaro | 269,07 x 13700 |
| Lettera | 269,49 x 21700 |
| Min-Max giorno | 265,14 - 270,65 |
| Intervallo di 52 settimane | 228,65 - 312,99 |
| Volume | |
| Media Volume | 702.026 |
| Capitalizzazione | 130,817B |
| Beta (5 anni mensile) | 0,29 |
| Rapporto PE (ttm) | 34,03 |
| EPS (ttm) | 7,92 |
| Prossima data utili | 13 feb 2024 |
| Rendimento e dividendo (futuro) | 3,81 (1,40%) |
| Data ex dividendo | 11 mar 2024 |
| Stima target 1A | 308,21 |
GlobeNewswireuniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL BehringLEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial sale of HEMGENIX® in the United States by its partner, global biotechnology leader CSL (ASX: CSL). HEMGENIX® (etranacoge
GlobeNewswireKapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysisST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England’s National Institute for Health and Care Excellence (NICE) has recomme
GlobeNewswireOTC Markets Group Welcomes CSL Limited to OTCQX
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited (ASX: CSL; OTCQX: CSLLY), a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology, has qualified to trade on the OTCQX® Best Ma
